OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS

CompletadoFase 3ClinicalTrials.gov

ID: NCT00925002Tipo: INTERVENTIONALInicio: 5 de ago de 2009Fin estimado: 8 de jul de 2020

Traducción no disponible, mostrando original

Resumen

This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD). In addition, this study continued to provide tafamidis to Val30Met subjects who had completed Protocol Fx-006 (a 1-year, open-label extension study to Protocol Fx-005 which was a randomized, double-blind, placebo-controlled, 18-month study to evaluate the safety and efficacy of tafamidis) or non-Val30Met subjects who had completed Protocol Fx1A-201 (a Phase 2, open-label study to evaluate TTR stabilization, safety, and tolerability of tafamidis) for up to 10 years or until subjects had access to tafamidis for ATTR-PN via prescription. Upon regulatory approval for the treatment of ATTR-PN in their respective country and access to prescription tafamidis, subjects may have been withdrawn from the study. Such subjects were considered study completers.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Subject had successfully completed either Protocol Fx-006 or Fx-1A-201.
Male or female subjects with ATTR-PN who had not undergone liver or heart transplantation at time of enrollment.
If female, subject was post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control

Criterios de exclusión

Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs)
Pregnant or breast feeding female subjects.
Clinically significant medical condition that, in the opinion of the investigator, would place the subject at an increased risk to participate in the study.
An alanine aminotransferase (ALT) and aspartate aminotransferase (AST) value \>3 × upper limit of normal (ULN) that, in the medical judgment of the investigator, was due to reduced liver function or active liver disease.
Sexually active males with partners of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 3 months after last dose of study drug.

Intervenciones

drug

Tafamidis

20 mg oral Fx-1006A daily

Ubicaciones

FLENI

Buenos Aires, Argentina

Patrocinadores

PrincipalPfizer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN ... | EligiMed